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To evaluate the impact of prior adjuvant chemotherapy on response rate (RR), progression-free (PFS) and overall survival (OS) of
metastatic breast cancer patients treated with epirubicin/paclitaxel (ET) regimens. In all, 291 patients enrolled in five studies in
metastatic breast cancer were analysed: 101 (35%) were chemonaive, 109 (37%) had received adjuvant CMF and 81 (28%) adjuvant
anthracyclines. Response rate to ET was 66%. Response rate was 63% for cyclophosphamide plus methotrexate plus 5-fluorouracil
(CMF), 67% for prior anthracyclines and 68% in chemonaive patients (P¼0.5). By multivariate analysis, adjusted odds ratio for
response was 0.81 (95% CI: 0.37–1.79) for CMF and 0.92 (95% CI 0.43–2.01) for anthracyclines (P¼0.86). The CR rates were 14%
for both CMF and anthracyclines and 22% for chemonaive patients (P¼0.2). By multivariate analysis, the relative odds of CR for CMF
or anthracyclines were 0.40 and 0.39 as compared to chemonaive patients (P¼0.036). The median PFS was 11.0 months for prior
CMF, 10.2 months for anthracyclines and 12.5 months in chemonaive patients (P¼0.33). In multivariate Cox’s model, a nonsignificant
increase in the risk of progression was seen in patients treated with adjuvant CMF or anthracyclines. The median OS was 23.8 months
for CMF, 20.2 months for anthracyclines and 27.5 months in chemonaive patients (P¼0.61). The same, nonsignificant, association
was seen in multivariate analysis. The ET regimens provide satisfactory results in metastatic breast cancer, regardless of previous
adjuvant chemotherapy.
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Metastatic breast cancer population is represented by a hetero-
geneous group of patients, and the objectives of therapy range
from symptom palliation and minimisation of toxicity in elderly
women with indolent disease to prolongation of survival in
younger women, with good performance status and aggressive
visceral disease. In particular, for patients with receptor-negative
disease, or for those whose disease has become resistant to
endocrine therapy and in whom impending organ failure requires
a rapid response, cytotoxic chemotherapy with the most active
drugs is generally the first treatment option to be considered.
The administration of anthracyclines was associated with an
increase in response rate (RR), remission duration and survival of
patients with metastatic disease, with approximately 20% of
complete responders still disease free 10 years after achieving a
complete response (CR) (Falkson et al, 1995; Rahman et al, 1999).
Moreover, an overview of randomized studies evaluating first-line
chemotherapy in metastatic disease showed that polychemother-
apy yields a higher RR on average than single-agent therapy, with
an increased RR for anthracycline-containing regimens over
nonanthracycline chemotherapy, while no clear differences in
survival were seen (A’Hern et al, 1993; Fossati et al, 1998).
In the adjuvant setting, anthracycline-containing regimens
showed a significant benefit in relapse-free and overall survival
(OS) as compared to cyclophosphamide plus methotrexate plus 5-
fluorouracil (CMF) (Early Breast Cancer Trialists’ Collaborative
Group, 1998). Therefore, the National Institute of Health (NIH)
and the St. Gallen International Consensus Panel on the Treatment
of Early Breast Cancer recommended adjuvant chemotherapy,
particularly with anthracyclines, for most women with early breast
cancer, regardless of nodal, menopausal or hormonal receptor
status (Eifel et al, 2001; Goldhirsch et al, 2001); as a consequence
anthracycline-containing regimens are used as adjuvant therapy in
the majority of patients with early breast cancer.
The relationship between the activity of first-line chemotherapy
for metastatic breast cancer and prior adjuvant treatment is
controversial, since some studies demonstrated a poorer outcome
(Chauvin et al, 1990; Bonneterre and Mercier, 1993; Venturini et al,
1996; Pierga et al, 2001) whereas others showed an outcome
similar to patients who had not received prior adjuvant
chemotherapy (Buzdar et al, 1981; Bitran et al, 1983; Valagussa
et al, 1986; Kardinal et al, 1988).
The objective of the present analysis was to evaluate the
prognostic impact of adjuvant chemotherapy with anthracyclines
on objective response rates, progression-free survival (PFS) and
OS of metastatic breast cancer patients treated with epirubicin/
paclitaxel (ET) regimens at the time of recurrence.
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lMATERIAL AND METHODS
Selection of patients
The patients included in this analysis were selected from five
consecutive prospective studies in metastatic breast cancer
coordinated by our institution; of these, four were phase II studies
and one was a randomised trial.
In all studies, the treatment under evaluation had to be a
combination of epirubicin and paclitaxel, and only patients
allocated to this treatment were included in the present analysis.
The chemotherapy regimens administered in each study and the
number of patients entered on each protocol are listed in Table 1.
Eligibility criteria were similar in the five studies. Patients were
required to have histologically confirmed breast cancer and
metastatic disease, with at least one bidimensionally measurable
lesion, previously untreated with chemotherapy for metastatic
disease. Prior adjuvant CMF was allowed if stopped at least 6
months before study entry; prior adjuvant anthracyclines were
permitted if the total cumulative dose was less than 280mgm
 2 in
case of doxorubicin and 360mgm
 2 in case of epirubicin and if
stopped at least 12 months before study entry; prior adjuvant
taxanes were not allowed. Other eligibility criteria included age less
than 75 years, Eastern Cooperative Oncology Group Performance
Status (ECOG–PS) p2 and left ventricular ejection fraction (L-VEF)
X50% at bidimensional echocardiography. Prior endocrine treat-
ment was allowed. Tumour responses were assessed according to
the World Health Organisation (WHO) criteria (Miller et al, 1981).
In all studies, cardiac evaluation was performed at baseline by
physical examination, chest radiograph, 12-lead ECG and detection
of L-VEF by bidimensionally echocardiography. Subsequent cardiac
evaluation consisted of physical examination, and ECG recording
every cycle, and echocardiography monitoring for L-VEF determi-
nation every two cycles during treatment, after the last course of
chemotherapy, and at 3-month intervals during the follow-up
period. The diagnostic criteria for CHF were new onset of dyspnoea,
presence of peripheral oedema, cardiac enlargement or pulmonary
congestion on chest radiograph, or pulmonary rales at auscultation.
At the occurrence of clinical symptoms of CHF, reduced L-VEF
contributed to diagnosis, and its assessment was performed by
bidimensional echography. Clinical cardiotoxicity was graded
according to the New York Heart Association clinical criteria for
cardiac failure (Criteria Committee of the New York Heart
Association: Nomenclature and Criteria for Diagnosis of Diseases
of the Heart and Great Vessels (ed 8), 1979). The cumulative
probability of developing cardiac toxicity was computed according
to the life-table method, as reported previously (Gennari et al, 1999).
Results from these studies, as well as an analysis on the cardiac
safety of the ET combination, have been reported individually
(Conte et al, 1997, 2001a,b; Gennari et al, 1999; Baldini et al, 2002)
and all the data have been prospectively collected at the Trial
Office of Pisa Department of Medical Oncology (ET and
gemcitabine plus epirubicin plus taxol (GET) trials) or at the Trial
Centre of the National Cancer Research Institute of Genoa (Manta
and MIG 6 trials).
The present analyses were conducted on the database resulting
from the pooling of the original databases of the individual studies
that included 369 patients. In all, 78 patients with metastatic
disease at diagnosis were excluded, leaving 291 patients for the
present analyses. Of these patients, 10 were enrolled in the ET
study after its publication.
Statistical methods
The primary aim of the analysis was to assess the effect of previous
adjuvant chemotherapy, with or without anthracyclines, on overall
RR, CRR, PFS and OS.
All. analyses were conducted according to the intention to treat
principle, in that all eligible patients prospectively enrolled in the
individual studies were considered.
Univariate analyses used standard statistical methods, such as
the w
2 test for comparison of proportions and the Kaplan–Meier
estimator and the log-rank test for the estimation and comparison
of survival curves.
The probabilities of overall response and of CR were also
modelled in two separate multivariate logistic regression models as
a function of the following covariates: age, disease-free interval
(DFI), metastatic site, receptor status, nodal status, type of
adjuvant treatment. Cox’s proportional-hazard multivariate model
was similarly used to assess the prognostic impact of previous
adjuvant therapies on PFS and OS, while adjusting for the same
covariates. All multivariate analyses used a step-down procedure
based on the likelihood ratio test (Cox, 1958, 1972).
RESULTS
Patients’ characteristics
A total of 291 patients were enrolled in the five consecutive
protocols (Table 1). Of these, 101 patients (35%) were chemonaive
and 190 (65%) received prior adjuvant chemotherapy, consisting
of CMF in 109 patients (37%) and an anthracycline-containing
regimen in 81 patients (28%). In particular, all the patients
included in this analysis received the combination of 5-fluorouracil
600mgm
 2, epirubicin 60mgm
 2 and cyclophosphamide
600mgm
 2 for six courses as adjuvant anthracycline-containing
treatment. The median age at study entry was 55 years (range 30–
73 years); 72% of women less than 60 years of age had received
adjuvant chemotherapy vs 49% of women older than 60 years. The
median disease-free survival (from diagnosis of the primary
tumour to distant recurrence) was 57 months (range 1–271
months). The distribution of disease-free survival among patients
who had received chemotherapy was as expected, with peaks
between the 2nd and the 3rd year. A different distribution in DFI
was observed according to adjuvant treatment: among the 101
chemonaive patients, 14 (13.9%) had a DFI p1 year as compared
to one (0.9%) and two (2.5%) in CMF and anthracycline-pretreated
patients, respectively. Conversely, chemonaive patients were over-
represented among long-term disease free survivors as well. 11%
Table 1 Treatment protocols and regimens
Study Phase Treatment schedule
ET II Epirubicin 90mgm
 2 day 1+paclitaxel 135–225mgm
 2 day 1, q.3 weeks,  6/8 cycles
GET II Gemcitabine 1000mgm
 2 days 1 and 8+Epirubicin 90mgm
 2 day 1+paclitaxel 175mgm
 2 day 1, q.3 weeks,  6/8 cycles
GET II multicenter Gemcitabine 1000mgm
 2 days 1 and 8+Epirubicin 90mgm
 2 day 1+paclitaxel 175mgm
 2 day 1, q.3 weeks,  6/8 cycles
MANTA II Epirubicin 90mgm
 2 day 1+Paclitaxel 175mgm
 2 day 1, q.3 weeks 8 cycles
MIG 6 III Epirubicin 90mgm
 2 day 1+paclitaxel 200mgm
 2 day 1, q.3 weeks 8 cycles vs epirubicin 120mgm
 2 day 1 4 cycles
followed by Paclitaxel 225mgm
 2 day 1 4 cycles, q.3 weeks
Total no of patients 291
ET¼epirubicin/paditaxel; GET¼gemcitabine plus epirubicin plus taxel.
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received high-dose consolidation treatment with peripheral blood
stem cell support and 15% received prior hormonal therapy with
or without radiotherapy for metastatic disease. Patients’ char-
acteristics by prior adjuvant treatment are listed in Table 2.
Cardiac safety
Overall, symptomatic CHF (class III NYHA) occurred in 13
patients (4.5%), all showing symptoms after completion of
treatment: five of them developed CHF after a cumulative
epirubicin dose of 1080mgm
 2 (360mgm
 2 were administered
in the adjuvant setting), equivalent to724mgm
 2 of doxorubicin;
one after a cumulative epirubicin dose of 990mgm
 2 (360mgm
 2
in the adjuvant setting), equivalent to 663mgm
 2 of doxorubicin;
four after a cumulative epirubicin dose of 720mgm
 1 (two of them
received 360mgm
 2 as part of the adjuvant setting), equivalent to
482mgm
 2 of doxorubicin; one after a cumulative epirubicin
doses of 630mgm
 2, equivalent to 422mgm
 2 of doxorubicin and
two after a cumulative epirubicin dose of 540mgm
 2, equivalent
to 362mgm
 2 of doxorubicin.
Clinical activity
Overall, a response to first-line epirubicin plus paclitaxel was
observed in 192 patients (66%) (Table 3). In univariate analysis, an
association between prior adjuvant anthracyclines and overall RR
was not evident: RR was 68% in patients who had not received
prior adjuvant chemotherapy, 63% in patients who received prior
CMF and 67% in patients who received prior anthracyclines
(P¼0.5). This observation was confirmed in a multivariate logistic
regression model, with RR as the dependent variable: adjusted
odds ratio for response was 0.81 (95% CI: 0.37–1.79) for CMF and
0.92 (95% CI 0.43–2.01) for anthracyclines (w
2-2df¼0.29,
P¼0.86). Age of patients and DFI were significantly associated
with the probability of response.
Conversely, results for CPR suggested an influence of adjuvant
chemotherapy on the probability of a CR (Table 4). In fact, in
Table 2 Patients characteristics
Type of adjuvant chemotherapy
All patients None CMF Anthra-based
Characteristic
No. of patients 291 101 109 81
No (%) No (%) No (%) No (%)
Age (years)
o50 103 (35.4) 24 (23.8) 48 (44.0) 31 (38.3)
51–60 104 (35.7) 34 (33.7) 42 (38.5) 28 (34.6)
61–73 84 (28.9) 43 (42.6) 19 (17.4) 22 (27.2)
Performance status
0 255 (87.6) 85 (84.2) 97 (89.0) 73 (90.1)
1 31 (10.7) 14 (13.9) 11 (10.1) 6 (7.4)
42 5 (1.7) 2 (1.9) 1 (0.9) 2 (2.5)
Oestrogen receptor status
Positive 150 (51.5) 52 (51.5) 57 (52.3) 41 (50.6)
Negative 69 (23.7) 16 (15.8) 32 (29.4) 21 (25.9)
Unknown 72 (24.8) 33 (32.7) 20 (18.3) 19 (23.5)
Axillary nodes
Positive 136 (46.7) 20 (19.8) 72 (66.1) 44 (54.3)
Negative 75 (25.8) 53 (52.5) 8 (7.3) 14 (17.3)
Unknown 80 (27.5) 28 (27.7) 29 (26.6) 23 (28.4)
DFI
1year 17 (5.8) 14 (13.9) 1 (0.9) 2 (2.5)
1years to 3years 112 (38.5) 19 (18.8) 52 (47.7) 41 (50.6)
3years to 5years 62 (21.3) 21 (20.8) 24 (22.0) 17 (21.0)
45years 100 (34.4) 47 (46.5) 32 (29.4) 21 (25.9)
Dominant metastatic site
Viscera 206 (70.8) 65 (64.4) 80 (73.4) 61 (75.3)
Soft tissues 51 (17.5) 18 (17.8) 18 (16.5) 15 (18.5)
Bone 34 (11.7) 18 (17.8) 11 (10.1) 5 (6.2)
HDCT 32 (10.9) 10 (9.9) 12 (11.0) 10 (12.3)
HT 44 (15.1) 16 (15.8) 15 (13.7) 13 (16.0)
Median cumulative epi,
range (mgsqm
 2)
540 540 900
(90–720) (90–720) (450–1080)
CMF¼Cyclophosplamide plus methotrexate plus 5-fluorouracil; DFI¼disease-free interval.
HDCT¼High Dose Chemotherapy
HT¼Hormonal Therapy for Metastatic Disease
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first-line ET was observed among chemonaive patients, even
though the difference was not statistically significant (chemonaive
22% vs CMF 14% vs prior anthracyclines 14%, P¼0.2). However,
in multivariate analysis, a significant association between adjuvant
chemotherapy and probability of CR was seen in the final model,
where age and site, besides adjuvant chemotherapy, were the only
significant factors included in the equation. The model indicated
that, once age and site were adjusted for, the relative odds of
obtaining a CR in patients who had received adjuvant CMF or
anthracyclines were 0.40 and 0.39 as compared to chemonaive
patients (P¼0.036). It was worthy noting that the probability of
CR was strongly correlated with age, and no CR was observed
among the 41 patients older than 60years who had received
adjuvant chemotherapy, vs six out of 43 (14%) chemonaive
patients.
Progression-free survival (Table 5)
The median PFS after first-line epirubicin plus paclitaxel was 11.2.
months (range 8.2–15.8 months). In univariate analysis prior
adjuvant treatments failed to show relevant effects on PFS: median
PFS was 12.5 months in patients who had not received prior
adjuvant chemotherapy, 11.0 months in patients who received
prior CMF and 10.2 months in patients who received prior
anthracyclines (P¼0.33) (Figure 1). In multivariate Cox’s propor-
tional-hazard model, a nonsignificant increase in the risk of
progression was seen in patients treated with adjuvant CMF (HR
1.21, 95% CI 0.78–1.86) or anthracyclines (HR 1.42, 95% CI 0.91–
2.20) (w
2-2 df¼2.53, P¼0.28). DFI was the only factor signifi-
cantly associated with progression-free survival.
Overall survival (Table 6)
The median OS after first-line epirubicin plus paclitaxel was 24.1.
months (range 16.4–35.1 months), and it was 27.5 months in
patients who had not received prior adjuvant chemotherapy, 23.8
months in patients who received prior CMF and 20.2 months in
patients who received prior anthracyclines; however, this differ-
ence was not statistically significant (P¼0.61) (Figure 2). The
same, nonsignificant, association was seen in multivariate analysis,
for CMF (HR 1.16, 95% CI 0.68–1.99) and anthracyclines (HR 1.35,
95% CI 0.78–2.33) (w
2-2df¼1.24, P¼0.54). Age and DFI were
significantly associated with survival.
DISCUSSION
The correlation between the efficacy of chemotherapy at the time of
relapse and the previous use of adjuvant chemotherapy is still
controversial. Poorer outcomes were not consistently observed in
metastatic breast cancer patients previously treated with adjuvant
chemotherapy (Buzdar et al, 1981; Bitran et al, 1983; Valagussa et al,
1986; Kardinal et al, 1988), although a few studies reported a
detrimental effect (Chauvin et al, 1990; Bonneterre and Mercier,
1993; Venturini et al, 1996; Pierga et al, 2001). The present analysis
was aimed at assessing the impact of adjuvant chemotherapy with
anthracyclines on the outcome of 291 patients treated with the
combination of epirubicin and paclitaxel at the time of relapse.
Patients included in this analysis were prospectively enrolled in five
controlled trials and treated over a period of five years. Unlike most
previous studies, a large proportion (two of three) of our patients
had received adjuvant chemotherapy, with a sizeable proportion
receiving an anthracycline-containing regimen. As a consequence,
this study can better assess the effect of previous anthracyclines on
the probability of response and prognosis in patients with
metastatic disease undergoing modern first-line chemotherapy
regimens using epioublicin and Paclitaxel However, due to the
relatively low dose of prior anthracycline allowed (epirubicin
o360mgm
 2 and doxorubicin o280mgm
 2), the results of this
analysis might be applicable only to this specific subset of patients.
Furthermore, the patients included in this analysis were
prospectively enrolled, treated and followed in five phase II and
III clinical trials, and a significant selection bias can be ruled out,
as only patients with metastatic disease at diagnosis were excluded.
The main limitation of our study is its small size, which precludes
statistically stable estimates and firm clinical conclusions,
especially in the light of the potential confounding effect of
various factors, some of which are indeed associated with the use
of chemotherapy (eg age at diagnosis) and/or could not be
accurately assessed in all patients at the time of diagnosis of
metastatic disease (pathological and biological factors).
Table 3 Overall RR to first-line ET according to prior adjuvant chemotherapy
RR Multivariate analysis
Prior adjuvant chemotherapy No. of patients No % P-values Odds ratio 95% CI v
2 df P-value
None 101 69 68 1
CMF 109 69 63 0.81 0.37–1.79
Anthracycline 81 54 67 0.92 0.43–2.01 0.29 2
0.5 0.86
All patients 291 192 66
RR¼response rate; ET¼epirubicin/paditaxel; df¼degree of freedom; CMF¼Cyclophosplamide plus methotrexate plus 5-fluorouracil.
Table 4 CRR to first-line ET according to prior adjuvant chemotherapy
CRR Multivariate analysis
Prior adjuvant chemotherapy No. of patients No % P-value Odds ratio 95% CI v
2 df P-value
None 101 22 22 1 (ref)
CMF 109 15 14 0.40 0.17–0.98
Anthracycline 81 11 14 0.39 0.17–0.86 5.45 2
0.2 0.036
All patients 291 48 16
CRR¼Complete response rate; ET¼epirubicin/paclitaxel; df¼degree of freedom; CMF¼Cyclophosplamide plus methotrexate plus 5-fluorouracil.
Epirubicin/paclitaxel after adjuvant anthracyclines in MBC
A Gennari et al
965
British Journal of Cancer (2004) 90(5), 962–967 & 2004 Cancer Research UK
C
l
i
n
i
c
a
lOur results confirm the high level of activity of the administra-
tion of epirubicin and paclitaxel, either in combination or
sequence, with an overall RR of 66%. This might be due to the
introduction of a new active agent such as paclitaxel as well as to a
better selection of patients potentially responsive to chemotherapy.
Furthermore, adjuvant chemotherapy with or without anthracy-
clines does not seem to affect the probability of achieving a
response to first-line ET. An intriguing finding was the negative
association between the probability of CR and previous chemother-
apy, which in multivariate analysis achieved statistical significance.
It is worth noting that no CRs were observed in patients older than
60 years previously treated with adjuvant chemotherapy. Yet, this
negative effect appeared to be similar in patients treated with
adjuvant anthracyclines or CMF, since the odds of obtaining a CR
was reduced by 60% in both CMF- and anthracyclines-pretreated
patients compared to chemonaive patients.
While no effect of previous chemotherapy on PFS was seen,
there was some indication of a shorter survival in patients who had
received adjuvant chemotherapy, and particularly anthracyclines-
containing regimens, even though the difference fell short of
statistical significance. In fact by multivariate analysis the
probability of a poorer outcome was increased by 40% in terms
of PFS and by 35% in terms of OS. This finding could be
interpreted in the light of the reduced CRR observed in patients
who received adjuvant chemotherapy (A’Hern et al, 1993). As a
matter of fact, if only the small group of patients failing to achieve
a complete response as a consequence of adjuvant chemotherapy
experienced a detrimental effect on survival, this difference would
be diluted when the entire groups of patients are compared.
In accordance with previously reported studies (Bonneterre and
Mercier, 1993; Venturini et al, 1996; Pierga et al, 2001), in our
series, the risk of progression and death was increased in
pretreated patients, and particularly in those who received an
anthracycline in the adjuvant setting. However, when indirect
comparisons were performed, the magnitude of this difference was
minor of those reported previously, and did not reach statistical
significance. The inconsistency between our results and those of
previous analyses that suggested a negative prognostic impact of
adjuvant treatments could be attributed to a better selection of the
patients as well as to the regimens employed in our studies, and
Table 5 PFS after-first-line ET according to prior adjuvant chemotherapy
Multivariate Analysis
Prior adjuvant chemotherapy No. of patients Median PFS months (95% CI) P-value Hazard ratio 95% CI v
2 df P-Value
None 101 12.5 (9.3-15.8) 1 (ref)
CMF 109 11.0 (9.1-12.9) 1.21 0.78–1.86
Anthracycline 81 10.2 (8.2-12.1) 1.42 0.91–2.20 2.53 2
0.33 0.28
All patients 291 11.2 (8.2-15.8)
PFS¼Progression-free survival; ET¼epirubicin/paclitaxel; CI¼Confidence interval; df¼degree of freedom; CMF¼Cyclophosplamide plus methotrexate plus 5-fluorouracil.
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Figure 1 Kaplan–Meier estimate of PES by prior adjuvant therapy.
Table 6 OS after first-line ET according to prior adjuvant chemotherapy
Multivariate analysis
Prior adjuvant chemotherapy No. of patients Median OS months (95% CI) P-value Hazard ratio 95% CI v
2 df P-value
None 101 27.5 (19.9–35.1) 1 (ref)
CMF 109 23.8 (19.1–28.5) 1.16 0.68–1.99
Anthracycline 81 20.2 (16.4–24.0) 1.35 0.78–2.33 1.24 2
0.61 0.54
All patients 291 24.1 (16.4–35.1)
OS¼overall survival; ET¼epirubicin/paclitaxel; CI¼Confidence interval; df¼degree of freedom; CMF¼Cyclophosplamide plus methotrexate plus 5-fluorouracil.
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Figure 2 Kaplan–Meier estimate of OS by prior adjuvant therapy.
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(Ghersi et al, 2003).
With only 13 episodes of symptomatic CHF, anthracycline-
induced cardiotoxicity was not an issue in this analysis. Moreover,
in accordance with our previous report (Gennari et al, 1999), the
low incidence of CHF, up to cumulative epirubicin doses of
990mgm
 2, suggests that the ET regimen might be safely
administered even in case of prior adjuvant epirubicin.
Overall, this analysis confirms that modern chemotherapy
regimens, including epirubicin and paclitaxel, provide satisfactory
results in metastatic breast cancer patients, regardless of previous
adjuvant chemotherapy. Conversely, it suggests that the prob-
ability of CR is decreased in previously treated patients and
particularly in women older than 60years, even though the
consequences of this decrease on survival are not clear.
These findings do not provide direct evidence on the efficacy and
the importance of anthracyclines in chemotherapy regimens
administered to breast cancer patients relapsed after adjuvant
anthracyclines. Accordingly, the possibility that the same results
could be obtained with different regimens without cardiac toxicity
cannot ruled out. However, the high level of activity observed in
previously treated patients (460%) can hardly be attributed entirely
to paclitaxel, which in monochemotherapy is associated with a RR
ranging from 26 to 47% in anthracycline-pretreated patients (Gianni
et al, 1994; Fountzilas et al, 1996; Donadio et al,2 0 0 1 ) .
In conclusion, on the basis of these results, hormone negative or
refractory metastatic breast cancer patients should be treated with
first-line chemotherapy, including the most active agents, irre-
spective of prior adjuvant treatment.
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